BusinessAchillion Reports 2016 Fourth Quarter and Year-End Financial ResultsBy Nasdaq OMXFeb 23, 2017, 9:05 PM UTC
BusinessData Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated DiseasesBy Nasdaq OMXDec 5, 2016, 9:05 PM UTC
BusinessAchillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of HematologyBy Nasdaq OMXNov 3, 2016, 1:01 PM UTC
BusinessAchillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical ProgramsBy Nasdaq OMXNov 3, 2016, 1:00 PM UTC
BusinessAchillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement WorkshopBy Nasdaq OMXSep 6, 2016, 10:05 AM UTC
